MajorAntiretroviral, HIV protease inhibitor×Inhaled and intranasal corticosteroid
Updated · Methodology
Mechanism
Fluticasone propionate is cleared from the circulation very rapidly, mainly because CYP3A4 metabolises it to an inactive carboxylic acid (fluticasone summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Atazanavir inhibits this enzyme, and ritonavir, part of the recommended atazanavir regimen, inhibits it more strongly than atazanavir (atazanavir SmPC, European Medicines Agency, EMA). When ritonavir 100 mg twice daily was given with intranasal fluticasone propionate 50 micrograms four times daily for 7 days, fluticasone levels rose significantly. Endogenous cortisol fell by about 86%, and greater effects are expected with inhaled fluticasone propionate (EMA). Atazanavir without ritonavir can also raise fluticasone levels (EMA). The US fluticasone label lists atazanavir among strong CYP3A4 inhibitors (US Food and Drug Administration, FDA).
Symptoms
After marketing, Cushing's syndrome and adrenal suppression have been reported in people who took ritonavir with inhaled or intranasal fluticasone propionate (atazanavir summary of product characteristics, SmPC, European Medicines Agency, EMA). Inhaled corticosteroids can cause systemic effects, especially at high doses over long periods: Cushing's syndrome, cushingoid appearance, adrenal suppression, growth retardation in children and adolescents, decreased bone mineral density, cataract and glaucoma (fluticasone SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Prolonged treatment with high doses of inhaled corticosteroids can cause acute adrenal crisis. Its symptoms are usually vague and may include loss of appetite, abdominal pain, weight loss, tiredness, headache, nausea, vomiting, hypotension, decreased level of consciousness, hypoglycaemia and seizures. Trauma, surgery, infection or any rapid dose reduction can trigger a crisis (AEMPS).
Management
Atazanavir with ritonavir is not recommended with fluticasone or other glucocorticoids metabolised by CYP3A4 unless the potential benefit outweighs the risk of systemic corticosteroid effects. These effects include Cushing's syndrome and adrenal suppression (atazanavir summary of product characteristics, SmPC, European Medicines Agency, EMA). Consider reducing the glucocorticoid dose with close monitoring of local and systemic effects, or switching to a glucocorticoid that is not a CYP3A4 substrate, such as beclometasone. When the glucocorticoid is withdrawn, the dose may need to be tapered over a longer period (EMA). When atazanavir is taken without ritonavir, use fluticasone propionate with caution and consider alternatives, particularly for long-term use (EMA; atazanavir label, US Food and Drug Administration, FDA). For atazanavir with cobicistat, fluticasone is on the list of corticosteroids not recommended unless the benefit outweighs the risk. If they are still used together, patients are monitored for systemic reactions. Corticosteroids less dependent on CYP3A, such as nasal or inhaled beclometasone, are considered, particularly for long-term use (atazanavir/cobicistat SmPC, EMA). The fluticasone SmPC advises avoiding combinations with CYP3A inhibitors, including cobicistat-containing products, unless the benefit outweighs the increased risk of systemic reactions. If they are combined, patients are monitored for these reactions (fluticasone SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). The US fluticasone label lists atazanavir among strong CYP3A4 inhibitors whose use with fluticasone is not recommended (FDA). Refer to the ritonavir SmPC as well before starting atazanavir with ritonavir (EMA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Reyataz (atazanavir) prescribing information (2024)– DailyMed setid 165cff62-b284-4a27-a65d-9ec8a5bfcdd8, revisión 12/2024, secciones 4 y 7.3
- EMA: Ficha técnica: Atazanavir/cobicistat (EU/1/15/1025), sección 4.5 (2026)– EMA, Evotaz 300 mg/150 mg (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 1151025001, consultada 10/2026, secciones 4.3 y 4.5
- EMA: Ficha técnica: Atazanavir, Reyataz (EU/1/03/267), sección 4.4 (2026)– EMA, Reyataz 300 mg cápsulas (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 03267008, consultada 11/2026, sin fecha de revisión en CIMA, secciones 4.2, 4.3, 4.4 y 4.5 (CORTICOSTEROIDES)
- FDA: Evotaz (atazanavir and cobicistat) prescribing information (2025)– FDA, DailyMed setid 83db29d7-5d85-49d6-8cb6-740473365cf8 (E.R. Squibb & Sons), version 16, revised 05/2025, sections 4 and 7.3 (Corticosteroids)
- AEMPS: Ficha técnica: Fluticasona, Flixotide Accuhaler 100 microgramos (nº registro 60480), secciones 4.4 y 4.5 (2023)– AEMPS, CIMA, nº registro 60480 (Flixotide Accuhaler 100 microgramos/inhalación, polvo para inhalación, GSK), revisión 10/2023, secciones 4.4, 4.5 y 5.2
- FDA: Fluticasone Propionate HFA (fluticasone propionate) prescribing information (2023)– FDA, DailyMed setid 99249b31-bf0a-464f-8335-845279350dbe (Prasco Laboratories, manufactured by GlaxoSmithKline), version 6, revised 09/2023, sections 5.11 and 7.1